Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
    (Date:9/30/2014)... 2014 Follow us on LinkedIn ... type of cholesterol carrier or lipoprotein in the blood. ... cholesterol levels in the body, especially along the walls ... attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) is ... cholesterol levels on a regular basis, to assess an ...
    (Date:9/30/2014)... September 30, 2014 Genedata, ... for drug discovery and related life science ... has chosen Genedata Selector as its host-pathogen ... data. FUNGITECT is a European consortium dedicated ... diseases via individualized anti-fungal drug therapies. Genedata ...
    (Date:9/30/2014)... DEL MAR, Calif. , Sept. 30, 2014 /PRNewswire/ ... devices for women,s health announces its receipt of a ... The FemmyCycle menstrual cup has also received FDA clearance ... Health Canada, and the CE in Europe. This patent is ... design. In conjunction with this issuance, the company is releasing ...
    Breaking Biology Technology:Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2
    ... - Strong 10.3% Growth in First-Quarter Revenue ... in ophthalmic optics, today,announced consolidated revenue of EUR840.4 million for ... increase on the first quarter,of 2008. Excluding the currency effect, ... Despite contracting demand early in the year, revenue was ...
    ... the opening,ceremony of its new active pharmaceutical ingredient manufacturing ... take over the site that,had been manufacturing Lipitor(R) since ... 6th and the transaction closed on the 8th; going ... manufacture for Pfizer but,will mostly make use of the ...
    ... National Academy of Sciences for groundbreaking work in biochemistry and ... University of Dundee will be inducted into the ... meeting on Saturday, April 25 at 8:00 p.m. at the ... Philip is one of only four Scottish scientists ever inducted ...
    Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
    (Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
    (Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
    (Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
    Breaking Biology News(10 mins):Risky metabolism 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2
    ... efforts associated with REDD focus on the big picture ... tropics. A research expedition just underway, led by scientists ... the third piece necessary to inform a global REDD ... Through a series of participatory mapping workshops with indigenous ...
    ... Fitness Theory to predict and explain phenomena ranging from ... many successes, the theory became a cornerstone for modern ... theory in the prestigious journal, Nature. Now Nature ... Edward Allen Herre and William Wcislo, staff scientists at ...
    ... 2011 A new study published in the April 2011 ... indicates that inadequate nutrition is linked to a greater ... that inadequate nutrient intakes are a significant risk factor for ... multivitamin/mineral supplements is not associated with lower rates of anemia," ...
    Cached Biology News:Participatory mapping workshops underway in Congo 2Is blood thicker than water? 2Inadequate diet can lead to anemia in postmenopausal women 2Inadequate diet can lead to anemia in postmenopausal women 3
    ... BD BioCoat Collagen I 60 mm Culture ... Culture Dishes, tissue-culture treated polystyrene with a uniform ... Coating : Collagen I ,Surface ... 21.3 cm2 ,Dim nominal : ...
    ... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... 100 20 mm surface area 55 ...
    BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
    Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
    Biology Products: